Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus CORDRAN SP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus CORDRAN SP.
CARMOL HC vs CORDRAN SP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid